0
Procedures: Advancements in Lung Cancer Diagnostics and Treatment |

Patients With Oligometastatic Disease Limited to the Chest Are Optimal Candidates for Lung Stereotactic Body Radiotherapy

Rebecca Fega, MD; Uma Goyal, MD; Helen Ross, MD; Dawn Jaroszewski, MD; Harshita Paripati, MD; Kosiorek Heidi, MS; Thomas Daniels, MD; William Rule, MD; Steven Schild, MD; Sujay Vora, MD; Jonathan Ashman, MD
Author and Funding Information

Mayo Clinic Arizona, Scottsdale, AZ


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):978A. doi:10.1016/j.chest.2016.08.1084
Text Size: A A A
Published online

Extract

SESSION TITLE: Advancements in Lung Cancer Diagnostics and Treatment

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Wednesday, October 26, 2016 at 08:45 AM - 10:00 AM

PURPOSE: The aim of this study was to identify patients with pulmonary metastases who would be most likely to benefit from lung stereotactic body radiotherapy (SBRT).

METHODS: After institutional review board approval, we retrospectively identified 92 patients with 111 pulmonary metastases from any primary site treated with SBRT at our institution between 2008 and 2015. Gross tumor volume (GTV) was non-uniformly expanded to create an internal target volume (ITV) to encompass tumor motion. A 5 mm uniform expansion of the ITV was applied to create the planning target volume (PTV). Cone beam CT was used for daily image-guidance. The most common SBRT regimen was 48 Gy/4 fractions for peripheral lesions, and 50 Gy/5 fractions for central lesions. Toxicities were recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Survival curves were calculated from the time of SBRT using the Kaplan-Meier method.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543